Research priorities for an HIV cure: international AIDS society global scientific strategy 2021
Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …
treatment is required and there is no cure. HIV can integrate in the host genome and persist …
Cell‐based delivery systems: emerging carriers for immunotherapy
Z Li, Y Wang, Y Ding, L Repp… - Advanced Functional …, 2021 - Wiley Online Library
Immunotherapy is leading a paradigm shift in the treatment of various diseases, including
tumors, auto‐immune diseases, and infectious diseases. However, the limited response rate …
tumors, auto‐immune diseases, and infectious diseases. However, the limited response rate …
In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice
Transplantation of B cells engineered ex vivo to secrete broadly neutralizing antibodies
(bNAbs) has shown efficacy in disease models. However, clinical translation of this …
(bNAbs) has shown efficacy in disease models. However, clinical translation of this …
Broadly neutralizing antibodies for HIV-1 prevention
SR Walsh, MS Seaman - Frontiers in immunology, 2021 - frontiersin.org
Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …
To bnAb or not to bnAb: defining broadly neutralising antibodies against HIV-1
SA Griffith, LE McCoy - Frontiers in immunology, 2021 - frontiersin.org
Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …
Protein engineering strategies for rational immunogen design
TM Caradonna, AG Schmidt - npj Vaccines, 2021 - nature.com
Antibody immunodominance refers to the preferential and asymmetric elicitation of
antibodies against specific epitopes on a complex protein antigen. Traditional vaccination …
antibodies against specific epitopes on a complex protein antigen. Traditional vaccination …
Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion
AD Nahmad, Y Raviv, M Horovitz-Fried, I Sofer… - Nature …, 2020 - nature.com
ABSTRACT HIV viremia can be controlled by chronic antiretroviral therapy. As a potentially
single-shot alternative, B cells engineered by CRISPR/Cas9 to express anti-HIV broadly …
single-shot alternative, B cells engineered by CRISPR/Cas9 to express anti-HIV broadly …
Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo
Due to their unique longevity and capacity to secrete high levels of protein, plasma B cells
have the potential to be used as a cell therapy for protein replacement. Here, we show that …
have the potential to be used as a cell therapy for protein replacement. Here, we show that …
[HTML][HTML] High-performance polymer electrolyte membranes incorporated with 2D silica nanosheets in high-temperature proton exchange membrane fuel cells
Silica nanosheets (SN) derived from natural vermiculite (Verm) were successfully
incorporated into polyethersulfone–polyvinylpyrrolidone (PES–PVP) polymer to fabricate …
incorporated into polyethersulfone–polyvinylpyrrolidone (PES–PVP) polymer to fabricate …
Broadly neutralizing antibodies targeting HIV: Progress and challenges
Anti-HIV broadly neutralizing antibodies (bNAbs) offer a novel approach to treating,
preventing, or curing HIV. Pre-clinical models and clinical trials involving the passive transfer …
preventing, or curing HIV. Pre-clinical models and clinical trials involving the passive transfer …